COVID UPDATE — KRIYA Institute is advising all ketamine providers to immediately stop providing in-office services in order to slow or halt the spread of Coronavirus. Existing ketamine patients should be moved to at-home ketamine treatment using compounded products.
Click here for more info
KRIYA Institute is devoted to understanding the therapeutic properties of ketamine (and related medicines). We provide clinical services directly to patients; we give presentations about therapeutic ketamine in a variety of settings; we offer consultation services to physicians and therapists; and we run the KRIYA Conferences, which is the first and largest conference in the world devoted to the use of ketamine. Our mission is to bring together the most rigorous Science and an appreciation of Spirit in the study of psychospiritual medicines such as ketamine.
We have experience in using ketamine to help patients with severe unipolar depression (major depression), bipolar depression, suicidal ideation, OCD, pain with depression, and a number of other difficulties. We also have an interest in the use of ketamine as an adjunct to psychotherapy for personal exploration.
We have worked with low dose ketamine following the NIMH protocol; we have worked with moderate dose ketamine to provide ketamine-faciliated psychotherapy; and we have worked with high dose ketamine to induce dissociative and mystical experiences. We also have an interest in using ultra low dose and ultra high dose ketamine. We have experience with most of the routes of ketamine administration: IV (infusion), IM (injection), nasal, oral, sublingual, and transdermal. We believe that there is not one right way to use ketamine… we think that different patients are best served by different treatment strategies. We also have some experience with ketamine derivatives and other NMDA antagonists.